Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (NASDAQ: ACIU) generates frequent news flow as a clinical-stage biopharmaceutical company developing precision therapeutics and diagnostics for neurodegenerative diseases. Company updates often center on clinical trial progress for its active immunotherapies and small-molecule programs targeting misfolded proteins implicated in Alzheimer’s disease, Parkinson’s disease and other NeuroOrphan indications.
Investors following ACIU news can expect detailed reports on interim and top-line data from key studies, such as the Phase 2 VacSYn trial of ACI-7104.056 in early Parkinson’s disease and the Phase 2 ABATE and ReTain trials in Alzheimer’s disease. Recent releases have highlighted strong immunogenicity and favorable safety for ACI-7104.056, biomarker trends suggesting potential stabilization of Parkinson’s disease pathology, and peer-reviewed results for the Tau-targeting active immunotherapy ACI-35.030 published in eBioMedicine.
News items also cover AC Immune’s diagnostic imaging efforts, including preclinical and clinical updates on PET tracers like ACI-19626 for TDP-43 pathology, with data published in Nature Communications. Corporate communications frequently include quarterly financial results, cash runway disclosures, pipeline prioritization decisions, workforce adjustments, and information on collaborations with partners such as Janssen, Takeda and Lilly.
This ACIU news page aggregates these company-issued announcements and regulatory communications, giving readers a single place to review clinical milestones, scientific publications, conference presentations and strategic corporate actions. For those tracking AC Immune’s progress in precision prevention of neurodegenerative diseases, it provides an organized view of how the pipeline and partnerships are evolving over time.
AC Immune (NASDAQ: ACIU) appointed Prof. Catherine Mummery as Chair of its Clinical Advisory Board effective October 28, 2025.
Prof. Mummery leads cognitive disorders at NHNN and novel therapeutics at UCL, has been senior investigator on more than 20 early-stage studies, led the first clinical trial of a Tau gene‑silencing therapy, and served as an investigator on AC Immune’s Phase 1b/2a ACI-35.030 (JNJ-2056) study.
The CAB advises on clinical development and regulatory strategy; other members include Reisa Sperling, Murat Emre, Lon Schneider, Pierre Tariot, and Juan Fortea. Dr. Kaj Blennow is retiring from the CAB.
AC Immune (NASDAQ: ACIU) announced that preclinical data for its first-in-class TDP-43 PET tracer ACI-19626 were published in Nature Communications (2025). The report shows high affinity and selectivity for pathological TDP-43 over Abeta, tau and alpha-synuclein, no off-target binding across a panel of >100 targets, and a non-human primate pharmacokinetic profile with rapid brain uptake and fast, complete washout. Based on these data, ACI-19626 advanced into a Phase 1 clinical trial with an initial readout expected in Q4 2025. The tracer aims to enable PET-based diagnosis and patient stratification for TDP-43 proteinopathies including ALS, FTD and LATE.
AC Immune (NASDAQ: ACIU) announced the peer-reviewed publication of Phase 1b/2a trial results for its anti-pTau active immunotherapy in eBioMedicine. The study compared two formulations: ACI-35.030 and JACI-35.054 in early Alzheimer's disease patients.
Key findings showed that ACI-35.030, developed using AC Immune's SupraAntigen® technology, demonstrated superior performance by generating rapid and potent polyclonal response against pathological Tau forms after a single dose. The treatment maintained 94-100% response rates through week 74 in high-dose cohorts, with no clinically relevant safety concerns.
Based on these positive results, ACI-35.030 has advanced to a potentially registration-enabling Phase 2b ReTain clinical trial in preclinical Alzheimer's disease, becoming the first active immunotherapy targeting Tau to be investigated in approximately 500 participants.
AC Immune (NASDAQ: ACIU) has announced a strategic restructuring to optimize its pipeline focus and extend its cash runway. The company will implement a 30% workforce reduction while concentrating on its three clinical-stage active immunotherapy programs and key small molecule programs targeting NLRP3 and Tau.
The restructuring will extend the company's cash runway through Q3 2027, supported by current cash resources of CHF 127.1 million as of June 30, 2025. The company maintains its clinical timeline guidance, with interim data expected from ACI-7104.056 in H2 2025 and ACI-24.060 in H1 2026.
The implementation will be completed by the end of 2025, with cost reductions becoming fully effective in early 2026. Affected employees will receive severance packages and support for new employment opportunities.
AC Immune (NASDAQ: ACIU) reported Q2 2025 financial results and provided updates on its neurodegenerative disease pipeline. The company maintains a strong financial position with CHF 127.1 million in cash, providing runway into Q1 2027. Key highlights include positive interim results from the Phase 2 VacSYn trial of ACI-7104.056 for Parkinson's disease, showing a 20-fold increase in anti-α-syn antibodies.
The company has three active immunotherapies in Phase 2 development, including ACI-24.060 for Alzheimer's disease, with interim results expected in early 2026. Their NLRP3 inhibitor program (ACI-19764) has advanced to IND-enabling studies. Q2 financial results showed contract revenues of CHF 1.3 million and a net loss of CHF 21.2 million, improved from CHF 22.8 million in Q2 2024.
AC Immune reported Q1 2025 financial results, highlighting strong progress in its neurodegenerative disease therapeutics pipeline. The company maintains a solid cash position of CHF 145.7 million, providing funding into Q1 2027.
Key developments include positive interim Phase 2 results for ACI-7104.056, their anti-alpha-synuclein immunotherapy for Parkinson's disease, showing strong immunogenicity and favorable safety. The treatment induced anti-a-syn antibodies over 20-fold higher than placebo levels after four immunizations.
Q1 2025 financials show R&D expenses of CHF 15.9 million (up from CHF 15.2 million in Q1 2024) and G&A expenses of CHF 4.4 million (down from CHF 5.0 million). The company reported a net loss of CHF 19.0 million, compared to CHF 17.9 million in the same period last year.
Multiple milestones are expected throughout 2025, including additional Phase 2 data readouts and potential trial initiations across their therapeutic portfolio.
AC Immune (NASDAQ: ACIU) has reported positive interim results from its Phase 2 VacSYn clinical trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease. The treatment has demonstrated significant efficacy, producing anti-α-synuclein antibody levels over 20-fold higher than placebo after 4 immunizations.
The trial's Part 1 involves over 30 patients randomized at a 3:1 ratio (treatment:placebo). Key findings show that antibody responses were effectively induced at week 6 after 2 immunizations and were further enhanced with additional doses. The treatment has shown a favorable safety profile with no serious adverse events reported, with only mild side effects including injection site reactions and headaches.
Based on upcoming interim results in 2025, including pharmacodynamic and biomarker data, the company may proceed with Part 2 of the trial, expanding to up to 150 patients. This phase will evaluate disease progression through motor and non-motor symptoms, along with digital, imaging, and fluid biomarkers.
AC Immune (NASDAQ: ACIU) has announced multiple presentations at the upcoming International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) in Vienna, Austria, from April 1-5, 2025. The company will host an industry symposium on April 2, focusing on active immunotherapies for neurodegenerative diseases.
The symposium will feature presentations on:
- Disease modification in Parkinson's disease
- ACI-7104.056 Phase 2 trial VacSYn
- ACI-35.030/JNJ2056 Phase 2b Retain study
- ACI-24.060 Phase 1b/2 ABATE study
Additional oral presentations will cover Morphomer® small molecules targeting Tau, Morphomer-antibody drug conjugates, and therapeutic molecules targeting alpha-synuclein aggregation. The event will include presentations from AC Immune leadership, key opinion leaders, and collaboration partners from Johnson & Johnson Innovative Medicine.
AC Immune (NASDAQ: ACIU) reported its full year 2024 financial results, highlighting a landmark deal with Takeda worth $100 million upfront and potential milestones up to $2.1 billion plus royalties for ACI-24.060. The company received a CHF 24.6 million milestone payment from Janssen for enrollment progress in the JNJ-2056 Phase 2b trial.
Key financial metrics include:
- Cash position of CHF 165.5 million, providing funding into Q1 2027
- Contract revenues of CHF 27.3 million in 2024
- R&D expenses increased to CHF 62.6 million
- Net loss of CHF 50.9 million
Clinical progress includes positive interim safety data for ACI-24.060 in Down syndrome patients and encouraging results for ACI-7104.056 in Parkinson's disease. The company expects 2025 total cash expenditure between CHF 75-85 million.
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, has announced its participation in two major investor conferences in March 2025:
- Leerink Partners 2025 Global Healthcare Conference - Management will hold investor meetings on March 10, 2025
- Barclays 27th Annual Global Healthcare Conference - Management will conduct investor meetings on March 11, 2025
Interested parties can arrange one-on-one meetings with AC Immune's management team through their Leerink or Barclays representatives or by contacting AC Immune directly.